



CardioComm Solutions Inc. and Monebo Technologies Partner to Provide Heart Analysis and Management Software

VICTORIA, B.C., June 27, 2006 – CardioComm Solutions Inc. (TSX-V:CCG) ("CardioComm", the "Company"), has partnered with Monebo Technologies, Inc. ("Monebo") and will work together to integrate Monebo's unique ECGAnalyzer™ electrocardiogram (ECG) analysis system into CardioComm's ECG management software. These partnership efforts have allowed the Company to sign contracts valued over \$2 million over the next three years to provide innovative software solutions in the ambulatory heart monitoring market.

Monebo's ECGAnalyzer™ automatically identifies the key components of the ECG signal, allowing it to calculate and provide critical measurements and possible diagnoses. The patented technology is unique because it provides beat-by-beat detection and classification of cardiac electrical signals utilizing a platform that employs adaptive filtering. In this approach, the program recognizes patterns of data, similar to the logic a physician applies when interpreting diagnostic tests. This allows for precise assessment of heart electrical activity, even when there is significant noise present, as is often the case in ambulatory heart monitoring.

CardioComm provides both client server and web based software solutions for 12 lead, ambulatory event monitoring and ICD and pacemaker follow up. The new partnership allows CardioComm to continue to add unique products and capabilities for leading edge cardiac patient management.

"The ability to effectively analyze ambulatory ECGs, including single channel ECGs, provides a significant step forward in ECG management software", stated Stephen Martin, President of CardioComm. "Combining our technologies will provide an enhanced level of automation in ECG management. Automatic ECG analysis with oversight from a trained professional should result in significant time savings."

"We are excited to be working with CardioComm on these groundbreaking projects," said Dale Misczynski, President and CEO of Monebo. "Their unique products have been well accepted by the cardiology community due to their advanced features, ease of use, and excellent service. The goal in combining the two company's technologies is to provide a seamless system, allowing our Customer's to increase their efficiency."

About Monebo Technologies, Inc. is a private company based in Austin, Texas, and a member of the Austin Technology Incubator, a part of the IC² Institute of the University of Texas in Austin. Monebo is a cardiac monitoring Solutions Company that develops technology to monitor, assess and

predict the electrical activity of the heart, and is focused on providing solutions to allow patients and physicians to manage and reduce problems associated with cardiac disease. Monebo is developing a highly accurate heart monitoring system that can be used anytime, anywhere, consisting of a simple chest strap, CardioBelt™ that transmits wirelessly to a cell phone or home computer. Monebo's proprietary digital signal processing algorithms, highly developed sensor technology, and wireless communication capabilities provide real-time monitoring information, with increased patient mobility.

About CardioComm Solutions Inc.

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification

On behalf of the Board of Directors of CardioComm Solutions Inc.

“Stephen Martin”

Stephen R. Martin, President & CEO

For investor information, please contact:

Stephen Martin
1-877-744-1122

ir@cardiocomm.com

Copyright © 2006 [CardioComm Solutions Inc.](#) All rights reserved